Shares of Anterix (ATEX) have gained 36.1% over the past four weeks to close the last trading session at $36.21, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $55.33 indicates a potential upside of 52.8%.The average comprises three short-term price targets ranging from a low of $44.00 to a high of $72.00, with a standard deviation of $14.74. While the lowest estimate indicates ...

Shares of Tactile Systems Technology (TCMD) have gained 3.4% over the past four weeks to close the last trading session at $29.61, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $38 indicates a potential upside of 28.3%.The mean estimate comprises four short-term price targets with a standard deviation of $4.32. While the lowest estimate of $32.00 indicates an 8.1% increase fro ...

Shares of Nektar Therapeutics (NKTR) have gained 79.9% over the past four weeks to close the last trading session at $68.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $129.86 indicates a potential upside of 89.8%.The mean estimate comprises seven short-term price targets with a standard deviation of $25.1. While the lowest estimate of $102.00 indicates a 49.1% increase fro ...

SkyWest (SKYW) closed the last trading session at $101.92, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $128.33 indicates a 25.9% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $12.55. While the lowest estimate of $112.00 indicates a 9.9% increase from the current price level, the most optimistic analyst expect ...

Core Viewpoint - Aecom Technology (ACM) shares have increased by 6.8% in the past four weeks, closing at $103.86, with a potential upside of 25.7% based on Wall Street analysts' mean price target of $130.5 [1] Price Targets - The average of 12 short-term price targets ranges from a low of $100.00 to a high of $145.00, with a standard deviation of $14.18, indicating variability among analysts [2] - The lowest estimate suggests a decline of 3.7%, while the highest indicates a potential upside of 39.6% [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about ACM's earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.3%, with one estimate moving higher and no negative revisions [12] Zacks Rank - ACM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to potential biases in analysts' estimates [3][10] - A low standard deviation among price targets indicates a high degree of agreement among analysts, which can serve as a starting point for further research [9]

Core Viewpoint - Aldeyra Therapeutics, Inc. (ALDX) shows significant potential for upside, with a mean price target of $9 indicating a 65.8% increase from the current trading price of $5.43, which has already gained 28.1% over the past four weeks [1]. Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.22, where the lowest estimate is $7.00 (28.9% increase) and the highest is $10.00 (84.2% increase) [2]. - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, indicating a potential starting point for further research [9]. Earnings Estimates and Analyst Agreement - There is increasing optimism among analysts about ALDX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 19.4%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - ALDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]. - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a good guide for potential investment [14].

Core Viewpoint - Atle Fund Management AB increased its holdings in Gilead Sciences by 6.8% in Q3, indicating growing institutional interest in the biopharmaceutical company [2] Institutional Holdings - Norges Bank acquired a new stake in Gilead valued at approximately $2.15 billion in Q2 - Ameriprise Financial increased its stake by 397.6% in Q2, now owning 6,748,403 shares valued at $748.15 million after purchasing an additional 5,392,191 shares - Invesco Ltd. raised its position by 33.5% in Q2, now holding 13,521,228 shares worth $1.50 billion after buying 3,394,330 shares - Assenagon Asset Management increased its holdings by 164.4% in Q3, now owning 3,489,062 shares valued at $387.29 million after acquiring 2,169,266 shares - Vanguard Group lifted its stake by 1.6% in Q2, now owning 119,364,226 shares worth $13.23 billion after acquiring 1,893,401 shares - Institutional investors and hedge funds currently own 83.67% of Gilead's stock [3] Stock Performance - Gilead Sciences shares opened at $141.95, with a market cap of $176.11 billion - The stock has a price-to-earnings ratio of 22.01, a PEG ratio of 0.73, and a beta of 0.33 - The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45, and a quick ratio of 1.31 - The one-year low for the stock is $93.37, and the one-year high is $142.20 [4] Earnings Results - Gilead reported an EPS of $2.47 for the latest quarter, exceeding the consensus estimate of $2.16 by $0.31 - The company achieved a net margin of 27.88% and a return on equity of 51.86% - Quarterly revenue was $7.77 billion, surpassing the consensus estimate of $7.42 billion, and up 3.0% year-over-year - Analysts expect Gilead to post an EPS of 7.95 for the current year [5] Analyst Ratings - Leerink Partners raised their price target from $114.00 to $146.00, rating the stock as "outperform" - Rothschild & Co Redburn increased their target from $153.00 to $159.00 with a "buy" rating - Sanford C. Bernstein set a price objective of $135.00 with an "outperform" rating - Citigroup raised their target from $140.00 to $156.00 with a "buy" rating - HSBC lifted their target from $110.00 to $133.00 with a "hold" rating - The stock has a consensus rating of "Moderate Buy" with an average target price of $136.73 [6] Insider Activity - Director Kelly A. Kramer sold 2,805 shares at an average price of $127.10, totaling $356,515.50, reducing ownership by 67.69% - CFO Andrew D. Dickinson sold 3,000 shares at an average price of $124.31, totaling $372,930.00, a 1.95% decrease in ownership - Over the last 90 days, insiders sold 257,397 shares worth $33.39 million, with insiders owning 0.27% of the company's stock [8] Company Overview - Gilead Sciences, founded in 1987 and headquartered in Foster City, California, focuses on developing medicines for high unmet medical needs - The company is known for its antiviral therapies and has expanded into oncology, cell therapy, and inflammatory diseases [9][10]

Group 1 - Betterware de Mexico SAPI de C (BWMX) shares have increased by 33.4% over the past four weeks, closing at $18.22, with a mean price target of $23.33 indicating a potential upside of 28.1% [1] - The average price targets range from a low of $20.00 to a high of $30.00, with a standard deviation of $5.77, suggesting a variability in estimates; the lowest estimate indicates a 9.8% increase, while the highest suggests a 64.7% upside [2] - Analysts show strong agreement on BWMX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for BWMX has increased by 38% due to one estimate moving higher over the last 30 days without any negative revisions [12] - BWMX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While the consensus price target may not be a reliable indicator of the extent of BWMX's gains, it does provide a directional guide for price movement [14]

Core Viewpoint - UP Fintech Holding Limited (TIGR) shows potential for significant upside, with a mean price target of $13.31 indicating a 46.3% increase from its current price of $9.1 [1] Price Targets - The average price target consists of six estimates ranging from a low of $4.73 to a high of $17.50, with a standard deviation of $4.69, indicating variability among analysts [2] - The lowest estimate suggests a potential decline of 48%, while the highest indicates a possible upside of 92.3% [2] Analyst Sentiment - Analysts are optimistic about TIGR's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 30% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - TIGR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Price Movement Guidance - While the consensus price target may not be a reliable predictor of the extent of TIGR's gains, it does provide a useful indication of the expected direction of price movement [14]

Core Viewpoint - Ooma (OOMA) shares have increased by 2.1% recently, closing at $11.93, with analysts suggesting a potential upside of 56.2% based on a mean price target of $18.63 [1] Price Targets and Analyst Estimates - The mean price target consists of four short-term estimates with a standard deviation of $0.95, indicating variability among analysts; the lowest estimate is $18.00 (50.9% increase), while the highest is $20.00 (67.6% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price direction, although it does not guarantee that the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about Ooma's earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the past 30 days, one earnings estimate has increased, leading to a 5.1% rise in the Zacks Consensus Estimate for the current year [12] - Ooma holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead; empirical research indicates that they rarely predict actual stock price movements accurately [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]